Distigmine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Distigmine
Accession Number
DB13694
Type
Small Molecule
Groups
Experimental
Description

Distigmine is a parasympathomimetic agent with a longer duration of action and enhanced drug accumulation compared to Pyridostigmine and Neostigmine. It is an anticholinergic drug and long-acting reversible carbamate cholinesterase inhibitor that binds directly and competitively to the agonist binding sites of muscurinic receptors. Distigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide. It improves detrusor function thereby restoring normal voiding patterns in patients suffering from detrusor underactivity [2].

Structure
Thumb
Synonyms
Not Available
Categories
UNII
T940307O7B
CAS number
17299-00-2
Weight
Average: 416.521
Monoisotopic: 416.241258367
Chemical Formula
C22H32N4O4
InChI Key
AHZBEVXBKNYXPU-UHFFFAOYSA-N
InChI
InChI=1S/C22H32N4O4/c1-23-13-9-11-19(17-23)29-21(27)25(3)15-7-5-6-8-16-26(4)22(28)30-20-12-10-14-24(2)18-20/h9-14,17-18H,5-8,15-16H2,1-4H3/q+2
IUPAC Name
1-methyl-3-{[methyl({6-[methyl({[(1-methylpyridin-1-ium-3-yl)oxy]carbonyl})amino]hexyl})carbamoyl]oxy}pyridin-1-ium
SMILES
CN(CCCCCCN(C)C(=O)OC1=C[N+](C)=CC=C1)C(=O)OC1=C[N+](C)=CC=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Distigmine.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Distigmine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Distigmine.Experimental, Illicit
AcebutololDistigmine may increase the bradycardic activities of Acebutolol.Approved, Investigational
AcetylcholineThe risk or severity of adverse effects can be increased when Distigmine is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Distigmine.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Distigmine.Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be decreased when used in combination with Distigmine.Experimental
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Distigmine.Experimental, Investigational
AlprenololDistigmine may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Distigmine.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Distigmine.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Distigmine.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Distigmine.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Distigmine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Distigmine is combined with Arecoline.Experimental
ArotinololDistigmine may increase the bradycardic activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Distigmine.Investigational
AtenololDistigmine may increase the bradycardic activities of Atenolol.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be decreased when used in combination with Distigmine.Approved, Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Distigmine.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Distigmine.Approved, Vet Approved
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Distigmine.Approved, Investigational
BefunololDistigmine may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Distigmine.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Distigmine.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Distigmine.Approved, Vet Approved
BetaxololDistigmine may increase the bradycardic activities of Betaxolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Distigmine is combined with Bethanechol.Approved
BevantololDistigmine may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Distigmine.Approved, Investigational
BisoprololDistigmine may increase the bradycardic activities of Bisoprolol.Approved
BopindololDistigmine may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe therapeutic efficacy of Bornaprine can be decreased when used in combination with Distigmine.Experimental
BucindololDistigmine may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Distigmine.Approved
BufuralolDistigmine may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololDistigmine may increase the bradycardic activities of Bupranolol.Approved
ButylscopolamineThe therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Distigmine.Approved, Investigational, Vet Approved
CarbacholThe risk or severity of adverse effects can be increased when Distigmine is combined with Carbachol.Approved
CarteololDistigmine may increase the bradycardic activities of Carteolol.Approved
CarvedilolDistigmine may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololDistigmine may increase the bradycardic activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Distigmine is combined with Cevimeline.Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Distigmine.Withdrawn
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Distigmine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Distigmine.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Distigmine.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Distigmine.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Distigmine.Approved
CloranololDistigmine may increase the bradycardic activities of Cloranolol.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Distigmine.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Distigmine.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Distigmine.Approved, Investigational
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Distigmine.Approved
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Distigmine.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Distigmine.Approved, Investigational
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Distigmine.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Distigmine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Distigmine.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Distigmine.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Distigmine.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Distigmine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Distigmine.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Distigmine.Withdrawn
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Distigmine.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Distigmine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Distigmine.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Distigmine.Approved
DipyridamoleThe therapeutic efficacy of Distigmine can be decreased when used in combination with Dipyridamole.Approved
EmeproniumThe therapeutic efficacy of Emepronium can be decreased when used in combination with Distigmine.Experimental
EpanololDistigmine may increase the bradycardic activities of Epanolol.Experimental
EpibatidineThe risk or severity of adverse effects can be increased when Distigmine is combined with Epibatidine.Experimental
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Distigmine.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Distigmine.Approved
EsmololDistigmine may increase the bradycardic activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Distigmine.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Distigmine.Approved
EtanautineThe therapeutic efficacy of Etanautine can be decreased when used in combination with Distigmine.Experimental
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Distigmine.Approved
EtybenzatropineThe therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Distigmine.Experimental
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Distigmine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Distigmine.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Distigmine.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Distigmine.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Distigmine.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Distigmine.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Distigmine.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Distigmine.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Distigmine.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Distigmine.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Distigmine.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Distigmine.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Distigmine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Distigmine.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Distigmine.Approved, Investigational, Withdrawn
GallamineThe therapeutic efficacy of Gallamine can be decreased when used in combination with Distigmine.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Distigmine.Approved
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Distigmine.Approved, Investigational, Vet Approved
GTS-21The risk or severity of adverse effects can be increased when Distigmine is combined with GTS-21.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Distigmine.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Distigmine.Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Distigmine.Experimental
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Distigmine.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Distigmine.Approved, Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Distigmine.Approved
IndenololDistigmine may increase the bradycardic activities of Indenolol.Withdrawn
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Distigmine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Distigmine.Investigational
LabetalolDistigmine may increase the bradycardic activities of Labetalol.Approved
LandiololDistigmine may increase the bradycardic activities of Landiolol.Investigational
LevobunololDistigmine may increase the bradycardic activities of Levobunolol.Approved
LobelineThe risk or severity of adverse effects can be increased when Distigmine is combined with Lobeline.Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Distigmine.Approved
MazaticolThe therapeutic efficacy of Mazaticol can be decreased when used in combination with Distigmine.Experimental
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Distigmine.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Distigmine.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Distigmine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Distigmine.Vet Approved
MepindololDistigmine may increase the bradycardic activities of Mepindolol.Experimental
MethacholineThe risk or severity of adverse effects can be increased when Distigmine is combined with Methacholine.Approved, Investigational
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Distigmine.Approved, Investigational
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Distigmine.Approved, Vet Approved
Methylscopolamine bromideThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Distigmine.Approved
MetipranololDistigmine may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Distigmine.Approved
MetoprololDistigmine may increase the bradycardic activities of Metoprolol.Approved, Investigational
MivacuriumDistigmine may decrease the neuromuscular blocking activities of Mivacurium.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Distigmine.Approved, Vet Approved
NadololDistigmine may increase the bradycardic activities of Nadolol.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Distigmine.Investigational
NebivololDistigmine may increase the bradycardic activities of Nebivolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Distigmine is combined with Nicotine.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Distigmine.Investigational
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Distigmine.Approved
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Distigmine.Experimental, Investigational
OxitropiumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Distigmine.Investigational
OxprenololDistigmine may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Distigmine.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Distigmine.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Distigmine.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Distigmine.Approved
PenbutololDistigmine may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Distigmine.Approved
PhenglutarimideThe therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Distigmine.Experimental
PilocarpineThe risk or severity of adverse effects can be increased when Distigmine is combined with Pilocarpine.Approved, Investigational
PindololDistigmine may increase the bradycardic activities of Pindolol.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Distigmine.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Distigmine.Approved
Platelet Activating FactorDistigmine may increase the bradycardic activities of Platelet Activating Factor.Experimental
PractololDistigmine may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Distigmine.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Distigmine.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Distigmine.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Distigmine.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Distigmine.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Distigmine.Approved, Experimental, Investigational
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Distigmine.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Distigmine.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Distigmine.Approved, Investigational
PropranololDistigmine may increase the bradycardic activities of Propranolol.Approved, Investigational
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Distigmine.Approved, Investigational
RapacuroniumDistigmine may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Distigmine.Approved
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Distigmine.Approved, Investigational
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Distigmine.Approved
SotalolDistigmine may increase the bradycardic activities of Sotalol.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Distigmine.Approved
TalinololDistigmine may increase the bradycardic activities of Talinolol.Investigational
TertatololDistigmine may increase the bradycardic activities of Tertatolol.Experimental
TimololDistigmine may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Distigmine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Distigmine.Approved, Withdrawn
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Distigmine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Distigmine.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Distigmine.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Distigmine.Approved, Investigational
TropatepineThe therapeutic efficacy of Tropatepine can be decreased when used in combination with Distigmine.Experimental
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Distigmine.Approved, Investigational
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Distigmine.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Distigmine.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Distigmine.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Distigmine.Approved
VareniclineThe risk or severity of adverse effects can be increased when Distigmine is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Distigmine.Approved
Food Interactions
Not Available

References

General References
  1. Harada T, Fushimi K, Kato A, Ito Y, Nishijima S, Sugaya K, Yamada S: Demonstration of muscarinic and nicotinic receptor binding activities of distigmine to treat detrusor underactivity. Biol Pharm Bull. 2010;33(4):653-8. [PubMed:20410601]
  2. Bougas DA, Mitsogiannis IC, Mitropoulos DN, Kollaitis GC, Serafetinides EN, Giannopoulos AM: Clinical efficacy of distigmine bromide in the treatment of patients with underactive detrusor. Int Urol Nephrol. 2004;36(4):507-12. [PubMed:15787326]
External Links
KEGG Compound
C16823
PubChem Compound
3116
PubChem Substance
347829310
ChemSpider
3004
ChEBI
80756
ChEMBL
CHEMBL1199307
Wikipedia
Distigmine
ATC Codes
N07AA03 — Distigmine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000462 mg/mLALOGPS
logP-2.7ALOGPS
logP-5.6ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)19.23ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area66.84 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity116.06 m3·mol-1ChemAxon
Polarizability47.47 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-methylpyridinium compounds. These are methylpyridines that carry a methyl group at the 1-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Methylpyridines
Direct Parent
N-methylpyridinium compounds
Alternative Parents
Pyridinium derivatives / Heteroaromatic compounds / Carbamate esters / Organic carbonic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
show 1 more
Substituents
N-methylpyridinium / Pyridinium / Carbamic acid ester / Heteroaromatic compound / Carbonic acid derivative / Azacycle / Organic oxide / Organopnictogen compound / Organic oxygen compound / Organooxygen compound
show 6 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyridinium ion (CHEBI:80756)

Drug created on June 23, 2017 14:46 / Updated on March 02, 2018 04:29